All Type of News
ALK NSCLC treatment, ‘Zykadia’ will be applied for insurance benefit
As approved in the health insurance benefit, another ALK(Anaplastic Lymphoma Kinase) positive non-small cell lung cancer treatment can now be clinically used.
In the ‘Announced Amendment on Drugs Prescribed for Cance...
“41 pharmaceutical companies poured KRW 5.6 billion into symposiums”
The Korea Pharmaceutical Manufacturers Association’s member companies were aggregated to support funds of KRW 5.6 billion on domestic and foreign symposiums.
According to the analysis result of the companies’ suppor...
Salesmen decrease while demands on R&D, manufacturing personnel increase
It was observed a manpower shortage on R&D, manufacturing and quality professionals is getting worse in the pharmaceutical industry.
Moreover, along with the Hanmi Pharm’s jackpot technology exports and the pharmace...
KMA to suggest telephone counseling as official agenda
It seems a discussion is going to start between doctors and the government about the ‘Demo Chronic Disease Management Project with Local Clinics.’
At the Association’s Press Center on the 20th, President Moo-jin Choo...
MOHW carries forward ‘Time Incentive System on Clinics’
The Ministry of Health and Welfare(MOHW) will carry forward a demo project of the ‘incentive system on time’ on clinics for the next year’s first half.
This is an answer to the suggestion of requesting incentives bas...
Status on Trajenta’s patent suits, will it lead to ‘composition’ too?
The Boehringer Ingelheim’s antidiabetic which recorded KRW 26.1 billion outpatient prescriptions only in the first half of the year, ‘Trajenta’ has become a target of many pharmaceutical companies to nullify its paten...
Innovative pharmaceutical companies earn KRW 102 out of KRW 1,000 products
I was analyzed innovative pharmaceutical companies earned KRW 102 out of selling products of KRW 1,000 products last year, and Pharma Research Products and Celltrion earned more than KRW 400.
According to the Yakup S...
Only 10 innovative pharmaceutical companies spent over 10% on R&D
It was surveyed there were only less than 10 companies which exceeded 10% in the R&D expense rate against sales among innovative pharmaceutical companies.
Moreover, it was observed there were the total 4 innovative ...
MOHW, “We will start Demo Chronic Disease Management Project from September”
The Ministry of Health and Welfare(MOHW) officially announced the start of the ‘Demo Chronic Disease Management Project Including Telephone Consultation’ from September, which has divided the medical industry into the...
Launch of Aspirin complex, Plavix A
‘Plavix A,’ a complex which combined an antiplatelet agent, ‘Plavix 75mg(generic name: clopidogrel),’ and aspirin(100mg) will be launched.
The launch of the Plavix/aspirin complex raised an expectation on convenience...
